Answers are grounded in this paper and cite their sources.
Two binuclear metal-radical complexes, formed by the reaction of M(hfac)(2) x 2H(2)O (M = Mn or Ni; hfac = hexafluoroacetylacetonate) with the 1,5-dimethyl-3-(4,6-dimethylpyrimidin-2-yl)-6-oxoverdazyl radical (3), were synthesized. The binuclear Mn complex 5 (i.e., 3[Mn(hfac)(2)](2)) crystallizes in the monoclinic space group C2/c: C(30)H(17)N(6)O(9)F(24)Mn(2), a = 29.947(3), b = 17.143(3), c = 16.276(3) A, beta = 123.748(3)*, Z = 4. The compound consists of two pseudo-octahedral Mn(II) ions, both bearing two hfac ancillary ligands, bridged by the bis(bidentate) radical 3. The temperature dependence of the magnetic susceptibility of 5 reveals moderate antiferromagnetic exchange between each of the Mn(II) ions and the verdazyl radical (J = -48 cm(-1)). The S = 9/2 ground spin state of the complex was corroborated by low-temperature magnetization versus field measurements. In contrast, the magnetic susceptibility versus temperature behavior of 6 (whose molecular structure is presumed to be analogous to that of 5) indicates that the two Ni(II) ions are strongly ferromagnetically coupled to the verdazyl radical (J = +220 cm(-1)). The magnetization versus field behavior of 5 is consistent with an S = 5/2 ground-state species.
No takes yet. Share an insight, caveat, or question.
Barclay et al. (2001) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: